吉西他滨联合顺铂化疗对非小细胞肺癌患者肿瘤标志物的影响  

Effect of gemcitabine combined with cisplatin on tumor markers in patients with non-small cell lung cancer

作　　者：王磊[1] 李飞[1] 黄晓日[1] 刘伟[1] WANG Lei LI Fei HUANG Xiao-ri LIU Wei(Department of Respiratory Medicine, Rizhao City People＇s Hospital, Rizhao 276826, Chin)

机构地区：[1]山东省日照市人民医院呼吸内科,日照276826

出　　处：《中国肿瘤临床与康复》2017年第4期408-410,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨吉西他滨联合顺铂化疗对非小细胞肺癌患者肿瘤标志物变化的影响。方法选取2014年3月至2014年9月间山东省日照市人民医院收治的90例非小细胞肺癌患者,采用随机数字表法分为GP组(吉西他滨+顺铂)与DP组(多西紫杉醇+顺铂),每组45例,对比两组患者临床疗效、肿瘤标志物变化、卡氏功能状态(Karnofsky)评分、无进展生存期和总生存时间。结果GP组患者治疗总有效率为75.6%,DP组为77.8%,两组比较,差异无统计学意义(P>0.05)。治疗后与治疗前相比,两组患者的肿瘤标志物糖类抗原50(CA50)、细胞角蛋白19片段(CYFRA21-1)和癌胚抗原(CEA)水平均降低,差异均有统计学意义(均P<0.05),而两组患者相比,以上肿瘤标志物水平差异均无统计学意义(均P>0.05)。两组患者的Karnofsky评分、无进展生存期和总生存时间,差异均无统计学意义(均P>0.05)。结论吉西他滨联合顺铂治疗非小细胞肺癌患者疗效突出,能降低肿瘤标志物水平,延长生存时间,提高患者生活质量。Objective To explore the impact of gemcitabine combined with cisplatin on the change of tumor markers in patients with non-small cell lung cancer. Methods From March 2014 to September2014,90 patients with non-small cell lung cancer who treated at Rizhao City People＇s Hospital were selected. Using a random number table,patients were divided into GP（ gemcitabine plus cisplatin） and DP（ docetaxel plus cisplatin） group with 45 patients in each group. Clinical curative efficacy,changes of tumor markers,Karnofsky score,progression-free survival and overall survival time were compared between the two groups. Results The overall efficacy rate was 75. 6% for GP group and 77. 8% for DP group（ P〈0. 05）. Compared with before treatment,carbohydrate antigen 50（ CA50）,cytokeratin-19 fragments（ CYFA21-1）,and carcino-embryonic antigen（ CEA） levels reduced in both groups after treatment（ all P〈0. 05）. After treatment,there was no significant difference in CA50,CYFA21-1 and CEA between the two groups（ all P〉0. 05）. There was no significant difference in Karnofsky score,progression-free survival and overall survival time between the two groups（ all P〈0. 05）. Conclusion Gemcitabine plus cisplatin has prominent curative efficacy in the treatment of non-small cell lung cancer,which lower levels of tumor markers,prolong the survival time,and improve the quality of life.

关 键 词：吉西他滨 顺铂 多西紫杉醇 癌 非小细胞肺 肿瘤标志物 

分 类 号：R734.2[医药卫生—肿瘤]